UMMS Affiliation
Psychotic Disorders Program, Department of Psychiatry
Publication Date
2018-03-05
Document Type
Article
Disciplines
Medical Pharmacology | Mental Disorders | Pharmacology | Psychiatry | Substance Abuse and Addiction
Abstract
Objective: The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia.
Methods: Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon monoxide (CO) level and cigarettes smoked per week were measured at baseline and week 24.
Results: There was no significant difference between two groups in changes in weight, BMI, fasting lipids, or cigarette smoking measures (p's > 0.05)
Conclusion: Naltrexone and bupropion combination treatment didn't show weight loss or smoking cessation effect in patients with schizophrenia in this pilot study.Implications for future studies were discussed. ClinicalTrials.gov identifier: NCT02736474.
Keywords
Schizophrenia, bupropion, naltrexone, smoking cessation, weight loss
Rights and Permissions
Copyright © 2018 Lyu, Du, Zhan, Wu, Su, Zhu, Jarskog, Zhao and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
DOI of Published Version
10.3389/fphar.2018.00181
Source
Front Pharmacol. 2018 Mar 5;9:181. doi: 10.3389/fphar.2018.00181. eCollection 2018. Link to article on publisher's site
Journal/Book/Conference Title
Frontiers in pharmacology
Related Resources
PubMed ID
29563871
Repository Citation
Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y, Jarskog F, Zhao M, Fan X. (2018). Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia. Open Access Articles. https://doi.org/10.3389/fphar.2018.00181. Retrieved from https://escholarship.umassmed.edu/oapubs/3350
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Included in
Medical Pharmacology Commons, Mental Disorders Commons, Pharmacology Commons, Psychiatry Commons, Substance Abuse and Addiction Commons